| apixaban 2.5mg versus placebo | |||
| AMPLIFY EXT 2.5mg, 2013 | apixaban (2.5 mg and 5 mg, twice daily) versus placebo | patients with venous thromboembolism who had completed 6 to 12 months of anticoagulation therapy | |
| apixaban 5mg versus placebo | |||
| AMPLIFY EXT 5mg, 2013 | apixaban (2.5 mg and 5 mg, twice daily)
versus placebo | patients with venous thromboembolism who had completed 6 to 12 months of anticoagulation therapy | |
| aspirin versus placebo | |||
| ASPIRE, 2012 | aspirin, at a dose of 100 mg daily, for up to 4 years versus placebo | patients who had completed initial anticoagulant therapy after a first episode of unprovoked venous thromboembolism | Follow-up duration: 37.2 months median |
| WARFASA, 2012 | aspirin, 100 mg daily for 2 years versus placebo | patients with first-ever unprovoked venous thromboembolism who had completed 6 to 18 months of oral anticoagulant treatment | |
| dabigatran versus placebo | |||
| RESONATE, 2013 | dabigatran at a dose of 150 mg twice daily versus placebo | ||
| dabigatran versus warfarin | |||
| REMEDY, 2013 | dabigatran at a dose of 150 mg twice daily versus | ||
| idraparinux versus placebo | |||
| Van Gogh, 2007 NCT00071279 | once-weekly injections of 2.5 mg of idraparinux for 6 months without monitoring versus placebo | patients who had completed 6 months of prophylaxis with idraparinux or a vitamin K antagonist and in whom extended anticoagulation was warranted | double-blind |
| low-intensity warfarin versus placebo | |||
| PREVENT, 2003 | low-intensity warfarin (target INR, 1.5 to 2.0) versus placebo | Patients with idiopathic venous thromboembolism who had received full-dose anticoagulation | double-blind Follow-up duration: 2.1 years mean |
| rivaroxaban 10mg versus aspirin | |||
| EINSTEIN CHOICE (10mg), 2017 NCT02064439 | Rivaroxaban 10 mg once daily for 12 months
versus ASA (Acetylsalicylic Acid) 100 mg once daily for 12 months | Patients with confirmed symptomatic DVT (Deep Vein Thrombosis) or PE (Pulmonary embolism) who completed 6 or 12 months of treatment of anticoagulation | |
| rivaroxaban 20mg versus aspirin | |||
| EINSTEIN CHOICE (20mg), 2017 NCT02064439 | Rivaroxaban 20 mg once daily for 12 months versus ASA (Acetylsalicylic Acid) 100 mg once daily for 12 months | Patients with confirmed symptomatic DVT (Deep Vein Thrombosis) or PE (Pulmonary embolism) who completed 6 or 12 months of treatment of anticoagulation | |
| rivaroxaban 20mg versus placebo | |||
| EISNTEIN EXT, 2010 | rivaroxaban alone (20 mg once daily)for an additional 6 or 12 months versus placebo | patients who had completed 6 to 12 months of treatment for venous thromboembolism | |
| VKA versus control | |||
| AUREC FVII, 2009 | continue VKA for additional 24 months versus discontinuation | patients with first spontaneous VTE and FVIII levels >230 IU/dl after 6 montsh of VKA | Follow-up duration: 37 months mean |
| DACUS (Siragusa), 2008 NCT00438230 | anticoagulants for 9 additional months versus no treatment | with a first episode of deep vein thrombosis, treated with OAT for 3 months and with Residual vein thrombosis | |
| DURAC II, 1997 | anticoagulant therapy continued indefinitely versus six months of oral anticoagulant therapy | patients who had had a second episode of venous thromboembolism | Follow-up duration: 4 years |
| PROLONG (Palarati), 2006 NCT00264277 | resume treatment versus discontinue treatment | patients with a first unprovoked proximal deep-vein thrombosis or pulmonary embolism who had received a vitamin K antagonist for at least 3 months and with abnormal D-dimer testing 1 month after the discontinuation of anticoagulation | Follow-up duration: 1.4 years |
| WODIT DVT, 2001 | continuation for nine additional months versus discontinuation | Patients with a first episode of idiopathic proximal deep venous thrombosis who had completed three months of oral anticoagulant therapy | Follow-up duration: at least two years |
| WODIT PE, 2003 | Extended oral anticoagulant therapy versus | patients after a first episode of pulmonary embolismwho had had 3 months of oral anticoagulant therapy without experiencing recurrence or bleeding | |
| VKA versus placebo | |||
| PADIS-PE (Couturaud), 2015 NCT00740883 | additional 18-month treatment with warfarin versus placebo | patients who had experienced a first episode of symptomatic unprovoked pulmonary embolism (ie, with no major risk factor for thrombosis) and had been treated initially for 6 uninterrupted months with a vitamin K antagonist | double-blind |
| warfarin versus control | |||
| Vitotec, 2009 | continuation of warfarin for another 6 months versus discontinuation of warfarin | patients with idiopathic DVT After 6 months of standard therapy (heparin/LMWH, warfarin with target INR 2-3) and persistent echogenic masses of over 20% of venous diameter | |
| warfarin versus low intensity warfarin | |||
| ELATE, 2003 | continue warfarin therapy with a target international normalized ratio (INR) of 2.0 to 3.0 versus target INR of 1.5 to 1.9 (low intensity) | patients who had completed three or more months of warfarin therapy for unprovoked venous thromboembolism | open-label Follow-up duration: 2.4 years mean |
| warfarin versus placebo | |||
| LAFIT, 1999 | warfarin for a further 24 months versus placebo | patients who had completed 3 months of anticoagulant therapy for a first episode of idiopathic venous thromboembolism | double-blind Follow-up duration: 10 months |
| Levine, 1995 | continue warfarin (targeted International Normalized Ratio 2.0 to 3.0) for a further eight weeks versus placebo | Patients with venographically confirmed acute proximal DVT who had received four weeks of warfarin after initial heparin and whose four week IPG was normal | |
| ximelagatran versus placebo | |||
| THRIVE 3, 2003 | ximelagatran (24 mg) versus placebo | patients with venous thromboembolism who had undergone six months of anticoagulant therapy | |
in first
in second
-
About
-
Browse pathology
|
treatment
-
Site map
-
Credits
Made with in Lyon
-
Contact us
-
Privacy policy
-
